1011-17-2

Basic information

• Product Name: 1-(2-HYDROXYPHENYL)PIPERAZINE
• Synonyms: RARECHEM AH CK 0117;N-(2-HYDROXYPHENYL)PIPERAZINE;2-(1-PIPERAZINO)PHENOL;1-(2-HYDROXYPHENYL)PIPERAZINE;LABOTEST-BB LT01596124;o-(1-piperazinyl)phenol;2-piperazin-1-ylphenol;2-(1-Piperazinyl) phenol
• CAS NO: 1011-17-2
• Molecular Formula: C₁₀H₁₄N₂O
• Molecular Weight: 178.23096
• EINECS: 213-782-5
• Product Categories: Piperidines, Piperidones, Piperazines;Building Blocks;C10;Chemical Synthesis;Heterocyclic Building Blocks;Piperazines
• Mol File: 1011-17-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 125-129 °C
• Boiling Point: 328.2 °C at 760 mmHg
• Flash Point: 152.3 °C
• Appearance: brown-pink to brown powder and chunks
• Density: 1.141
• Vapor Pressure: 0.000101mmHg at 25°C
• PKA: 11.25±0.35(Predicted)
• BRN: 10646
• CAS DataBase Reference: 1-(2-HYDROXYPHENYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-HYDROXYPHENYL)PIPERAZINE(1011-17-2)
• EPA Substance Registry System: 1-(2-HYDROXYPHENYL)PIPERAZINE(1011-17-2)

Safety Data

• Hazard Codes: T,Xi
• Statements: 25-36/37/38
• Safety Statements: 26-37/39-45
• RIDADR: UN 2811 6.1/PG 3
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 1011-17-2(Hazardous Substances Data)

Usage

Chemical Properties

brown-pink to brown powder and chunks

Uses

2-(Piperazin-1-yl)phenol is used in preparation of substituted imidazoles and oxazoles in the treatment of cancers and other medical conditions.

InChI:InChI=1/C10H14N2O/c13-10-4-2-1-3-9(10)12-7-5-11-6-8-12/h1-4,11,13H,5-8H2/p+1

Upstream product

• 95-56-7 2-hydroxybromobenzene 
• 313657-51-1 tert-butyl 4-(2-hydroxyphenyl)piperazine-1-carboxylate 
• 58260-69-8 1-(2-hydroxyphenyl)piperazine dihydrobromide 
• 35386-24-4 1-(2-Methoxyphenyl)piperazine 

Downstream Products

• 137965-81-2 1-{5-[4-(2-Hydroxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-pyrrolidin-2-one 
• 133347-36-1 O-desmethyl-naftopidil 
• 110645-23-3 (7R,8S)-7-Hydroxy-8-{3-[4-(2-hydroxy-phenyl)-piperazin-1-yl]-propyl}-2-methoxy-7,8-dihydro-6H-5-oxa-9-thia-benzocycloheptene-8-carboxylic acid methyl ester; hydrochloride 
• 386214-65-9 N,N-dimethyl-2,2-diphenyl-4-[4-(2-hydroxyphenyl)piperazin-1-yl]butanamide 
• 667905-10-4 2-{4-[2-hydroxy-3-(thiochroman-8-yloxy)-propyl]-piperazin-1-yl}-phenol 
• 913734-83-5 2-[4-(2-hydroxyphenyl)piperazin-1-ylmethyl]indole-5-carbonitrile 
• 952750-64-0 N-[5-(4-{[4-(2-hydroxyphenyl)piperazin-1-yl]carbonyl}phenyl)-4-methyl-1,3-thiazol-2-yl]guanidine 
• 129526-90-5 4-methyl-5-[2-(4-o-hydroxyphenylpiperazin-1-yl)ethyl]thiazole 
• 189762-98-9 2-(4-methylpiperazin-1-yl)phenol 
• 1114334-43-8 4-{3-[4-(2-hydroxyphenyl)piperazin-1-yl]propoxy}-4-aza-tricyclo[5.2.1.0^2,6]dec-8-ene-3,5-dione 

Relevant articles and documents

Identification of novel GLUT inhibitors

The compound class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS as very potent inhibitors of facilitated glucose transporter 1 (GLUT1). Extensive structure–activity relationship studies (SAR) of each ring system of the molecular framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine). The selectivity against GLUT2 was excellent and initial in vitro and in vivo pharmacokinetic (PK) studies are encouraging.

CYCLOHEXYLDIAMINES AS SELECTIVE ALPHA 1A/1D ADRENORECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATE HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS

The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable form thereof, as dual selective a1a / a 1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

New μ-opioid receptor agonists with piperazine moiety

New μ-opioid receptor (MOR) agonists containing piperazine and homopiperazine moieties in the structures were synthesized and their affinities to and agonist potencies on MOR were evaluated. Among the synthesized compounds, 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide (20Aa) showed the highest affinity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells, and the highest agonist potency on the MOR in isolated guinea-pig ileum preparation.